ÖZET
İlk kez Çin’in Wuhan kentinde Aralık 2019’da ortaya çıkan salgından sorumlu olan etkenin yeni koronavirüs (2019-nCoV) olduğu saptanmıştır. Daha sonra, solunum yolu enfeksiyonuna yol açan bu virüsün beta-CoV ailesine ait olduğu belirlenip, şiddetli akut solunum yolu enfeksiyonu-koronavirüs-2 (SARS-CoV-2) olarak adlandırılmış ve oluşturduğu hastalığa da koronavirüs enfeksiyon hastalığı-19 (COVİD-19) denilmiştir. Çin’de başlayan salgın hızla Doğu Asya ülkelerine sonrasında Avrupa ve Amerika’ya yayılarak, tüm dünyayı etkisi altına almış ve Dünya Sağlık Örgütü tarafından pandemi olarak ilan edilmiştir. Bu derleme, bu virüsle ilgili genel bir bakış açısı sunmakla birlikte, hücre içindeki patogenezini ve konak immün yanıtlarını incelemeyi amaçlamıştır.
References
1
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24:490-502.
2
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
3
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74.
4
World Health Organization. (2020). https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---12-march-2020.
5
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032. [Epub ahead of print]
6
World Health Organization, Coronavirus disease (COVID-19) pandemic. (2020). Last Accessed Date: 30.06.2020 Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
7
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91-8.
8
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. New York: Springer; 2015:1-23.
9
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92.
10
Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011;85:4122-34.
11
Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein. J Virol 2014;88:1293-307.
12
Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher TA. Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry J Virol 2011;85:873-82.
13
Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020;14:407-12.
14
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith H, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172:577-82.
15
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
16
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620-9.
17
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
18
Xu Z, Shi L, Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet 2020;8:420-2.
19
Abbas AK, Lichtman AH, Pillai S. Basic Immunology: Functions and Disorders of the Immune System. 4th ed. Philadelphia: Elsevier Saunders; 2014.
20
Doan T, Melvold, Viselli S, Waltwnbaugh C. Lippincott’s illustrated reviews serisinden: İmmünoloji. Ed: Deniz G, Erten G, Camcıoğlu Y. Nobel Tıp Kitabevleri, 2. Basım, 2017.
21
Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 8th ed. Philadelphia: Elsevier Saunders; 2015.
22
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol 2020;215:108448.
23
Tay ZM, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nature Rev Immunol 2020;20:363-74.
24
Cron RQ, Chatham WW. The rheumatologist’s role in Covid-19. J Rheumatol 2020;47:639-42.
25
George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med 2014;5:69-86.
26
Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet (London, England) 2014;383:1503-16.
27
McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev 2020;19:102537.
28
Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020;20:269-70.
29
Wong CK, Lam CW, Wu AKL, Ip WK, Lee NLS, Chan HIS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95-103.
30
Min CK, Cheon S, Ha NY, Sohn KM, Kim Y, Aigerim A, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016;6:25359
31
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020;71:762-8.
32
Tan M, Liu Y, Zhou L, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology 2020;160:261-8.
33
McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020;19:102537.
34
Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020;16:1753-66.
